Introduction {#S1}
============

Natural killer (NK) cells are effector and immunomodulatory cells of the innate immune system. Through recognition of HLA class I molecules *via* activating and inhibitory killer cell immunoglobulin-like receptors (KIRs), and upon release of cytolytic granules, NK cells mediate killing of tumor and virus-infected cells and editing of dendritic cells, and play an important role in graft-versus-leukemia and graft rejection after hematopoietic stem cell transplantation (HSCT) ([@B1]--[@B4]). Furthermore, they can modulate immune responses by secreting chemokines and cytokines ([@B5], [@B6]).

Human peripheral blood contains two major NK cell subsets that can be distinguished based on the density of CD56 and CD16 expression on the cell surface: CD56^bright^ CD16^−/low^ and CD56^dim^ CD16^bright^ cells. These two NK cell subsets differ for the expression pattern of various other cell surface and intracellular molecules ([@B7]). In particular, CD56^bright^ cells express NKp46, CD94/NKG2A, and CCR7 at higher levels than CD56^dim^ NK cells, whereas CXCR1 and KIRs are more abundantly expressed by CD56^dim^ cells. Furthermore, CD56^bright^ and CD56^dim^ NK cells have distinct functional properties, with CD56^bright^ cells being potent producers of cytokines, and CD56^dim^ cells being active mediators of natural and antibody-dependent cellular cytotoxicity, as also reflected by higher intracellular levels of perforin and granzymes ([@B8], [@B9]). In healthy adults, CD56^bright^ cells comprise a minority (5--10%) of all circulating NK cells, but because they express CCR7, they are attracted to secondary lymphoid organs where they represent the predominant NK subset ([@B10], [@B11]). A subset of CD56^low^ KIR^+^ NK cells, expressing CD57 represent terminally differentiated NK cells, whereas a further subset expressing the CD56^−^ CD16^+^ CD57^+^ KIR^+^ phenotype are thought to represent exhausted NK cells ([@B12]).

*RAG1* and *RAG2* mutations in humans are associated with a broad spectrum of clinical and immunological phenotypes, including T^−^ B^−^ severe combined immune deficiency (SCID) ([@B13]), Omenn syndrome (OS) ([@B14]), atypical SCID (AS) ([@B15]--[@B17]), and combined immune deficiency with granuloma and/or autoimmunity (CID-G/A) ([@B18]--[@B21]). We have previously shown that the severity of the clinical and immunological phenotype in patients with *RAG* mutations correlates with the residual recombination activity of the mutant recombinase-activating gene (RAG) protein ([@B22]), which may differently affect diversity and composition of T and B cell receptor repertoires ([@B23]), whereas NK cell differentiation proceeds unaffected. For patients with severe *RAG* mutations presenting with SCID, OS, or AS, HSCT represents the only option of definitive cure; however, an increased rate of allograft rejection has been observed as compared to patients with other forms of SCID ([@B24], [@B25]). An important role of NK lymphocytes in mediating rejection of bone marrow allografts has been known for decades ([@B26]), but why patients with RAG deficiency would have a higher risk of graft rejection than other forms of NK^+^ SCID (such as IL7R or CD3 deficiency) remains unknown.

Although *RAG* genes are not required for NK cell development, data in mice indicate that Rag deficiency affects NK cell phenotype and function. It has been shown that expression of the *RAG* genes begins in common lymphoid progenitor cells that give rise to T, B, and NK cells ([@B27]--[@B29]). Studies in mice harboring transgenic reporters for Rag expression or recombinase activity have demonstrated the existence of two populations of mature NK cells: those that have been exposed to transient Rag expression during lymphoid differentiation (here termed as Rag^past^) and NK cells that were not previously exposed to Rag (Rag^naive^ NK cells) ([@B30]). These two populations differ for their proliferative capacity and interleukin-2 (IL-2)-mediated Stat5 phosphorylation, and a progressive decrease in the proportion of Rag^past^ cells has been observed during NK cell differentiation ([@B29]). Furthermore, Rag^naive^ NK cells display an activated phenotype, increased cytotoxicity, and enhanced apoptosis, thereby resulting in poor survival and impaired DNA damage response as compared to their Rag^past^ counterpart ([@B30]). It has been postulated that Rag expression in lymphoid progenitors would favor selection of cells with optimal levels of expression of proteins involved in DNA break repair, including ARTEMIS and DNA ligase 4 (LIG4), thereby marking functionally distinct subsets of NK cells, and providing Rag^past^ NK cells with improved survival and "fitness." If confirmed also in humans, the hypothesis that RAG deficiency results in the presence of NK cells with a distinctive phenotype and enhanced cytotoxic potential, would provide novel mechanistic insights to account for the high rate of primary graft failure, incomplete T cell reconstitution, and lack of B cell engraftment that are frequently observed following haploidentical HSCT for RAG deficiency, unless chemotherapy is used ([@B25]). To test this hypothesis, we have analyzed NK cell phenotype and function in a large cohort of patients with mutations in *RAG* and in other genes involved in non-homologous end joining (NHEJ), presenting with a variable severity of clinical and immunological manifestations, as compared to healthy donors of comparable age, and to patients with other forms of T or B cell lymphopenia.

Materials and Methods {#S2}
=====================

Patients and Controls {#S2-1}
---------------------

The patient population consisted of 66 subjects with molecularly confirmed biallelic mutations in gene involved in V(D)J recombination, in particular 35 patients with *RAG1*, 11 with *RAG2*, 15 with *DCLRE1C* (ARTEMIS), 3 with *LIG4*, and 2 with *NHEJ1* (Cernunnos/XLF) mutations. Based on the clinical and immunological phenotype (Table [1](#T1){ref-type="table"}), these patients were assigned to the following subgroups: T^−^ B^−^ NK^+^ SCID (*n* = 19), OS (*n* = 11), AS (*n* = 13), and delayed onset combined immune deficiency (CID, *n* = 23). For the purposes of analysis, patients with OS and with AS, were combined into a single group (OS/AS, *n* = 24).

###### 

Clinical, molecular, and immunological features of patients with mutations in *RAG* or non-homologous end-joining (NHEJ) genes.

  Patient ID   Phenotype                                  Age         Gene defect and mutation                     Lymphocyte subsets (cells/μL)   IgG (mg/dL)   IgA (mg/dL)   IgM (mg/dL)   IgE (kU/L)   Proliferation to phytohemagglutinin       Cytomegalovirus (CMV) status   EpsteinBarr virus (EBV) status   Infections   Autoimmunity       Granulomas   Skin rash                                                                                                                                                                                                          
  ------------ ------------------------------------------ ----------- -------------------------------------------- ------------------------------- ------------- ------------- ------------- ------------ ----------------------------------------- ------------------------------ -------------------------------- ------------ ------------------ ------------ ----------- ------------------------------------------------------------------------------------- -------------------------------------------------------------- ------------------------------------------------- --------------------------
  P1           Severe combined immune deficiency (SCID)   9 months    RAG1: p.R332X; p.R561H                       185                             74            24            0             166          883[^\^^](#tfn1){ref-type="table-fn"}     \<7                            \<5                              \<2          Absent             neg          neg         Rotavirus, *Pseudomonas*, Enterococcus enteritis                                      No                                                             No                                                No
  P2           SCID                                       2 months    RAG2: p.I218N; p.I218N                       25                              23            0             1             155          \<7                                       \<7                            \<5                              nd           nd                 neg          neg         PJP                                                                                   No                                                             No                                                No
  P3           SCID                                       10 months   RAG2: p.T125Rfs\*10; p.T125Rfs\*10           230                             230           4             0             352          929[^\^^](#tfn1){ref-type="table-fn"}     \<7                            \<5                              \<1          Absent             neg          neg         PJP, metapneumovirus, oral candidiasis                                                No                                                             No                                                No
  P4           SCID                                       2 months    RAG1: p.R841Q; p.F974L                       34                              30            4             265           395          371                                       22                             67                               38           Markedly reduced   neg          neg         No                                                                                    No                                                             No                                                No
  P5           SCID                                       2 weeks     RAG1: p.R507W; p.S966T                       286                             111           190           16            1,027        235                                       \<15                           18                               nd           Reduced            pos          nd          CMV viremia                                                                           No                                                             No                                                No
  P6           SCID                                       6 months    RAG1: p.E965X; p.E965X                       2                               2             0             0             252          \<7                                       \<7                            \<5                              nd           Absent             neg          neg         *Klebsiella pneumonia*                                                                No                                                             No                                                No
  P7           SCID                                       2 months    RAG1: p.M605I/R561C; p.F972S                 2                               1             0             0             275          325                                       \<7                            \<5                              nd           nd                 pos          neg         RSV bronchiolitis, adenovirus pneumonia, CMV                                          No                                                             No                                                No
  P8           SCID                                       6 months    RAG2: p.C41W; p.C41W                         5                               1             0             1             804          71                                        \<7                            \<5                              \<1          absent             neg          neg         Disseminated BCG                                                                      No                                                             No                                                No
  P9           SCID                                       5 months    RAG1: p.G720D; p.G720D                       9                               9             0             0             449          766                                       \<7                            \<5                              \<1          absent             neg          neg         Cutaneous *S. aureus* abscess                                                         No                                                             No                                                No
  P10          SCID                                       5 months    RAG1: p.C470Lfs\*55; p.C470Lfs\*55           236                             90            146           0             80           161                                       \<7                            \<5                              nd           nd                 neg          neg         No                                                                                    No                                                             No                                                No
  P11          SCID                                       1 week      RAG1: p.C176F; p.C176F                       23                              13            1             573           1,449        754                                       \<7                            \<5                              7.8          Absent             neg          neg         No                                                                                    No                                                             No                                                No
  P12          SCID                                       14 months   DCLRE1C: exon1_3del; exon1_3del              11                              0             4             10            1,248        722[^\^^](#tfn1){ref-type="table-fn"}     29                             16                               \<1          Absent             neg          neg         Disseminated BCG                                                                      No                                                             AFB ^+^ necrotizing granulomatous lymphadenitis   No
  P13          SCID                                       3 months    DCLRE1C: exon1_3del; exon1_3del              1,076                           1,070         10            0             904          50                                        \<7                            \<5                              nd           nd                 neg          neg         RSV pneumonia                                                                         No                                                             No                                                Yes
  P14          SCID                                       5 months    DCLRE1C: p.K157Kfs\*13; p.K157Kfs\*13        215                             152           61            40            287          540                                       38                             106                              nd           Markedly reduced   neg          neg         *Pseudomonas* bacteremia, recurrent otitis, skin abscesses, oral candidiasis          No                                                             No                                                Papular rash
  P15          SCID                                       1 week      DCLRE1C: exon1_3del; exon1_3del              0                               0             0             10            840          nd                                        nd                             nd                               nd           nd                 nd           nd          Sepsis                                                                                No                                                             No                                                No
  P16          SCID                                       23 months   DCLRE1C: p.Y199X; p.Y199X                    107                             50            63            0             498          1,350[^\^^](#tfn1){ref-type="table-fn"}   15                             \<5                              \<1          Absent             neg          neg         PJP, RSV pneumonia, cutaneous *Pseudomonas* infection, candidiasis                    No                                                             No                                                No
  P17          SCID                                       28 months   DCLRE1C: p.Y199X; p.Y199X                    46                              39            7             0             291          1,060                                     620                            nd                               nd           Absent             neg          neg         No                                                                                    No                                                             No                                                np
  P18          SCID                                       4 months    DCLRE1C: p.S32C; IVS11, +5g\>a               7                               1             0             1             598          115                                       \<7                            nd                               nd           Absent             neg          neg         Adenovirus hepatitis, oral ulcers                                                     No                                                             No                                                No
  P19          SCID                                       10 months   DCLRE1C: p.F393fs\*8; p.F393fs\*8            13,997 (maternal)               9,851         3,221         29            274          830[^\^^](#tfn1){ref-type="table-fn"}     \<7                            nd                               nd           nd                 pos          nd          Oral candidiasis                                                                      No                                                             No                                                Generalized erythroderma
  P20          Omenn syndrome (OS)                        2 months    RAG1: p.R396H; p.R396H                       15,760                          6,390         9,465         0             1,958        300                                       \<7                            \<5                              1,744        Reduced            pos          neg         Candidiasis, *E. coli* UTI                                                            No                                                             No                                                Generalized erythroderma
  P21          OS                                         1 month     RAG1: p.W959X; p.W959X                       3,424                           3,368         0             0             5,003        390                                       22                             16                               \<2          Absent             neg          neg         Rhinovirus                                                                            No                                                             No                                                Generalized erythroderma
  P22          OS                                         2 months    RAG1: p.R410Q; p.M435V                       19,230                          10,286        8,215         0             816          1,120                                     \<7                            101                              \>5,000      Markedly reduced   neg          neg         Rhinovirus                                                                            No                                                             No                                                Generalized erythroderma
  P23          OS                                         2 months    RAG1: p.R561C; p.R716W                       4,667                           3,976         696           0             7,231        \<7                                       \<7                            \<5                              233          Absent             neg          neg         No                                                                                    No                                                             No                                                Generalized erythroderma
  P24          OS                                         4 months    RAG1: p.R396C; p.R404Q                       15,751                          8,850         6,957         0             1,389        258                                       216                            \<5                              2,181        Absent             neg          neg         PJP, rhinovirus                                                                       No                                                             No                                                Generalized erythroderma
  P25          OS                                         2 months    RAG1: p.R561H; p.R624H                       11,140                          6,204         4,931         0             4,564        100                                       6                              302                              \>5,000      Markedly reduced   pos          neg         No                                                                                    Anti-smooth muscle ab                                          No                                                Generalized erythroderma
  P26          OS                                         6 months    RAG2: p.G95V; p.E480X                        2,671                           2,351         855           0             36           102                                       116                            235                              \<5          Markedly reduced   neg          neg         Impetigo, otitis                                                                      No                                                             No                                                Generalized erythroderma
  P27          OS                                         1 month     RAG1: p.R142X; p.M458fs\*33                  5,105                           5,029         228           15            4,458        634\*                                     17                             8                                \<2          Markedly reduced   pos          neg         Recurrent URTI/LRTI                                                                   No                                                             No                                                Generalized erythroderma
  P28          OS                                         1 month     RAG1: p.S259Afs\*5; p.S259Afs\*5             170                             155           15            0             320          815                                       \<7                            5                                14.4         Markedly reduced   neg          neg         *Enterococcus faecalis* bacteremia                                                    Intermittent neutropenia                                       No                                                Generalized erythroderma
  P29          OS                                         4 months    RAG1: p.R332X; p.L1025fs\*39                 34,115                          22,416        8,364         0             1,338        \<7                                       \<7                            \<5                              600          Reduced            neg          neg         Enterovirus pneumonia, Moraxella bacteremia                                           No                                                             No                                                Generalized erythroderma
  P30          OS                                         4 months    DCLRE1C: exon1_3del; spling defect intron6   26,295                          5,085         19,382        0             1,498        120                                       602                            26                               192          nd                 neg          neg         PJP, rhinovirus                                                                       No                                                             No                                                Generalized erythroderma
  P31          Atypical SCID (AS)                         Not known   RAG2: p.R123C; p.R123C                       1,056                           96            780           23            67           206                                       11                             14                               1            nd                 neg          pos         Skin abscess, recurrent pneumonia, candidiasis                                        Lymphadenopathy                                                No                                                No
  P32          AS                                         4 months    RAG1: p.H375D; p.H375D                       870                             610           210           350           390          370                                       nd                             89                               nd           Absent             nd           nd          Candidiasis                                                                           No                                                             No                                                Candida rash
  P33          AS                                         17 months   RAG1: p.R396C; p.M435V                       360                             180           150           31            370          1,036                                     \<7                            145                              77           Markedly reduced   neg          neg         Vaccine strain varicella zoster virus (VZV), chronic diarrhea                         AIHA, vasculitis                                               No                                                Vasculitis
  P34          AS                                         3 years     RAG1: p.H612R; p.A857V                       2,063                           225           878           612           1,068        2,080                                     \<7                            172                              1.9          Reduced            pos          neg         Adenovirus pneumonia, *Klebsiella pneumonia*, candidiasis                             ANA, TPO Ab                                                    No                                                No
  P35          AS                                         2 years     RAG1: p.F939C; p.F939C                       729                             110           266           41            733          1,260                                     55                             215                              78           normal             nd           nd          BCG infection                                                                         No                                                             No                                                No
  P36          AS                                         2 months    RAG1: p.T173fs\*27; p.T173fs\*27             399                             93            209           3             1,205        392                                       10                             \<5                              113          absent             pos          neg         Pneumonia                                                                             AIHA                                                           No                                                No
  P37          AS                                         16 months   RAG2: p.G35A; p.G35A                         716                             277           102           105           209          229                                       75                             327                              nd           Reduced            neg          pos         Recurrent pneumonia (P*seudomonas, Klebsiella, H. influenzae*), nail candidiasis      AIHA, psoriasis                                                NO                                                Psoriasis
  P38          AS                                         25 months   RAG1: p.R841W; p.R841W                       950                             220           20            121           665          538[^\^^](#tfn1){ref-type="table-fn"}     146                            54                               2            Normal             neg          neg         Adenovirus, rhinovirus                                                                Tubulointerstitial nephritis with lymphocytic infiltrate       No                                                No
  P39          AS                                         13 months   RAG1: p.K86Vfs\*33; p.K86Vfs\*33             1,010                           80            840           620           460          2,420                                     194                            328                              5.6          Markedly reduced   pos          pos         P*seudomonas* sepsis, CMV, BCGitis                                                    Miller-Fisher                                                  No                                                No
  P40          AS                                         4 years     DCLRE1C: p.T65I; p.T65I                      558                             207           243           36            108          560                                       19                             54                               5            nd                 nd           nd          HPV                                                                                   No                                                             No                                                Warts
  P41          AS                                         10 years    DCLRE1C: p.T65I; p.T65I                      683                             268           390           24            403          1,190                                     \<7                            87                               5            nd                 nd           nd          HPV, recurrent URTI/LRTI                                                              No                                                             No                                                Warts
  P42          AS                                         2 years     DCLRE1C: p.T65I; p.T65I                      547                             217           268           22            226          240                                       \<7                            35                               5            Absent             nd           nd          HPV, BCG                                                                              No                                                             No                                                Warts
  P43          AS                                         9 months    NHEJ1: p.R57X; p.R57X                        426                             299           98            259           265          600                                       \<7                            949                              nd           Reduced            neg          neg         Adenovirus                                                                            No                                                             No                                                No
  P44          CID                                        6 years     RAG2: p.T215I; p.T215I                       840                             560           180           70            190          2,480[^\^^](#tfn1){ref-type="table-fn"}   \<7                            170                              nd           Reduced            nd           pos         Recurrent URTI, intermittent diarrhea                                                 Neutropenia                                                    No                                                No
  P45          CID                                        19 years    RAG2: p.G35V; p.M322T                        457                             236           184           165           5,781        \<100                                     \<7                            \<5                              nd           Reduced            neg          pos         Single episode of RTI requiring admission at age 13 years                             No                                                             Skin granulomatosis                               Skin granulomas
  P46          CID                                        11 years    RAG1:p.R404Q; p.R404Q                        4,520                           3,300         1,220         61            1,004        \<200                                     \<7                            30                               nd           Absent             pos          pos         CMV retinitis, esophageal candidiasis, EBV                                            Colitis                                                        Colon granulomatosis                              No
  P47          CID                                        8 years     RAG1: p.H612R; p.H612R                       526                             361           144           373           106          859[^\^^](#tfn1){ref-type="table-fn"}     \<7                            \<5                              1            Markedly reduced   na           na          Recurrent pneumonia, MAC, cellulitis                                                  AIHA                                                           No                                                No
  P48          CID                                        17 years    RAG1: p.K86Vfs\*33; p.H612R                  581                             530           80            460           450          390                                       \<7                            38                               \<1          Reduced            pos          pos         Herpes zoster, *H. influenzae, Corynebacterium propinquum*, P*seudomonas*             ITP, vitiligo                                                  Lung granulomatosis                               No
  P49          CID                                        11 years    RAG1: p.L514R; p.L514R                       2,831                           1,658         837           0\*           309          \<140                                     \<7                            130                              \<18         normal             neg          pos         Recurrent URTI/LRTI, warts, molluscum, EBV-LPD                                        Autoimmune cytopenias                                          Granulomas in liver and lungs                     Warts, molluscum
  P50          CID                                        31 years    RAG2: p.F62L; p.F62L                         380                             225           162           78            215          1,000[^\^^](#tfn1){ref-type="table-fn"}   \<7                            25                               nd           nd                 na           na          Disseminated VZV, cryptococcus meningitis, URTI, *Pseudomonas* pneumonia              No                                                             Lung granulomatosis                               
  P51          CID                                        12 years    RAG1: p.R624H; p.Y728H                       665                             406           219           23            177          8                                         \<7                            10                               \<2          Normal             neg          pos         Moderately severe VZV, zoster, recurrent URTI/LRTI                                    No                                                             No                                                No
  P52          CID                                        9 years     RAG2: p.V8I; p.D400H                         2,253                           1,275         774           293           205          910                                       257                            33                               29           Normal             neg          neg         *S. pneumoniae* sepsis, severe VZV infection, recurrent URTI/LRTI, perianal abscess   No                                                             No                                                Severe atopic dermatitis
  P53          CID                                        16 years    RAG1: p.H612R; p.H612R                       629                             390           141           69            60           637                                       37                             45                               nd           Normal             neg          neg         Recurrent otitris, recurrent pneumonia, *S. aureus* skin infection                    Alopecia areata, AIHA, neutropenia                             No                                                No
  P54          CID                                        9 years     RAG1: p.R474C; p.L506F                       890                             500           400           300           130          560                                       20                             60                               5            Normal             neg          pos         VZV pneumonia, bronchiectasis                                                         No                                                             No                                                No
  P55          CID                                        39 years    RAG1: p.R108X; p.W522C                       532                             336           179           14            166          673                                       106                            69                               \<1          nd                 nd           nd          Pneumonia, warts, orolabial HSV, oral candidiasis, MRSA skin infection                Alopecia, autoimmune hypothyroidism, autoimmune hypogonadism   Vocal cord granuloma                              No
  P56          CID                                        16 years    RAG1: p.H375D; p.Y562C                       522                             468           18            72            6            1,346[^\^^](#tfn1){ref-type="table-fn"}   420                            320                              nd           Reduced            neg          neg         Pneumonia                                                                             ITP, neutropenia                                               Granulomatosis of skin, liver, spleen, lungs      No
  P57          CID                                        10 years    RAG1: p.R410W; p.H375D                       273                             169           42            56            150          597[^\^^](#tfn1){ref-type="table-fn"}     71                             87                               nd           Normal             neg          neg         Recurrent LRTI                                                                        Alopecia totalis, vitiligo, myasthenia gravis                  No                                                No
  P58          CID                                        40 years    RAG1: p.R108X; p.W522C                       362                             235           117           0\*           106          976                                       100                            33                               0            nd                 neg          neg         Recurrent URTI/LRTI, warts, mouth sores, oral and nail candidiasis                    Alopecia, vitiligo                                             No                                                No
  P59          CID                                        36 years    RAG2: p.N173S; p.E437K                       260                             204           54            0\*           134          1,050[^\^^](#tfn1){ref-type="table-fn"}   17                             17                               0            Reduced            neg          pos         Septis arthritis, recurrent pneumonia, warts                                          Alopecia, myositis                                             No                                                Psoriatic rash
  P60          CID                                        30 months   DCLRE1C: p.G126D; p.L70del                   2,800                           1,040         2,340         520           510          630[^\^^](#tfn1){ref-type="table-fn"}     \<7                            210                              \<2          Markedly reduced   neg          pos         Echovirus, adenovirus                                                                 AIHA                                                           no                                                Perianal rash
  P61          CID                                        2 years     DCLRE1C: p.T65I; p.T65I                      540                             160           240           16            1,320        135                                       \<7                            15                               nd           nd                 nd           nd          Recurrent URTI/LRTI, aphtous stomatitis                                               Lupus vulgaris                                                 No                                                Lupus vulgaris
  P62          CID                                        12 years    DCLRE1C: p.S147fs\*6; p.S147fs\*6            260                             170           90            2             1,635        173                                       \<7                            11                               2            nd                 neg          neg         JC virus-associated PML                                                               Vasculitis                                                     Cutaneous granulomatous vasculitis                Vasculitis
  P63          CID                                        7 years     NHEJ1: p.R57G; p.R57G                        693                             319           330           44            195          60                                        \<7                            104                              nd           Reduced            neg          neg         Recurrent URTI/LRTI                                                                   No                                                             No                                                No
  P64          CID                                        3 years     Ligase 4 (LIG4): p.R278H; p.R278H            3,088                           1,191         1,832         46            2,081        1,400[^\^^](#tfn1){ref-type="table-fn"}   \<7                            167                              nd           Normal             neg          pos         Chronic calicivirus                                                                   No                                                             No                                                No
  P65          CID                                        8 years     LIG4: p.K424Rfs\*20; p.R278H                 513                             214           289           96            438          622                                       \<7                            \<10                             2            Reduced            pos          pos         Pneumonia, otitis                                                                     No                                                             No                                                No
  P66          CID                                        17 years    LIG4: p.K449Q; p.R814X                       771                             308           410           12            140          149                                       \<7                            \<5                              \<1          Reduced            neg          neg         Recurrent URTI/LRTI, bronchiectasis, skin ringworm infection                          No                                                             No                                                No

*^\^^, on immunoglobulin replacement therapy; Ab, antibody; AIHA, autoimmune hemolytic anemia; ANA, anti-nuclear antibodies; BCG, bacillus calmette-guerin; CMV, cytomegalovirus; HPV, human papillomavirus; ITP, immune thrombocytopenia; LPD, lymphoproliferative disease; LRTI, lower respiratory tract infection; PJP, Pneumocystis jiroveci pneumonia; RSV, respiratory syncitial virus; TPO, thyroid peroxidase; URTI, upper respiratory tract infection; UTI, urinary tract infection; VZV, Varicella zoster virus*.

In addition, 22 patients with various other conditions characterized by numerical and/or functional defects of T lymphocytes served as a control for T cell deficiency. This group of other T cell defects (TCDs) included four patients with *CD3G* mutations, two patients with Di George syndrome, two patients with IL7R deficiency, and one patient each with mutations in *MSN, JAK3, IL2RG, CD3D, CD3E, RMRP* genes, or with MHC class II deficiency. In seven cases with T cell deficiency, the underlying diagnosis was unknown, including two infants with severe T cell lymphopenia diagnosed at birth with low T cell receptor excision circle (TRECs). Based on established criteria ([@B31]), 7 of these patients met definition of SCID (with \<300 T cells/μL), and the remaining 15 had either less severe numerical TCDs or had functional T cell abnormalities. None of these patients with TCD carried mutations in *RAG1/2, DCLRE1C, PRKDC, LIG4*, or *NHEJ1* genes.

As a control for B cell lymphopenia, nine patients with molecularly confirmed mutation in the *BTK* gene, causing X-linked agammaglobulinemia (XLA), were also studied.

Finally, 19 healthy infants (age ≤2 years) and 29 healthy subjects of \>2 years of age served as normal controls for patients with SCID and OS/AS, or for patients with CID, respectively.

The study was approved by the Institutional Review Boards of Boston Children's Hospital, the National Institute of Allergy and Infectious Diseases (protocols 93-I-0119 and 16-I-N139), and of all other referring centers. Blood samples were obtained upon written informed consent of the subject or, in the case of minors, of their parents or legal guardians. Because of limitations in blood volume and/or in the number of cells, not all analyses could be performed in each individual included in the study.

Analysis of NK Cell Phenotype {#S2-2}
-----------------------------

Peripheral blood was collected in EDTA- or heparin-containing vacutainers. Red blood cells were lysed from 200 µl of EDTA-blood using RBC lysis buffer (eBioscience). Cells were washed with FACS buffer (PBS containing 2% FBS), then equally distributed in five tubes and incubated for 1 h at 4°C with primary antibodies (Ab), as described below. After washing with FACS buffer, cells were incubated for 30 min at 4°C with secondary antibodies, washed again with FACS buffer, and incubated for 30 min at 4°C with conjugated antibodies. After washing, cells were re-suspended in FACS buffer and immediately analyzed on LSR Fortessa Flow Cytometer (BD) using FACS Diva v.6.1.3 software (BD). NK cells were defined as CD56^+^ CD3^−^ CD20^−^ CD14^−^ cells. Final analysis on the expression of NK cell markers was performed using FloJo v.10.2 (TreeStar). The antibodies used to define NK cell phenotype were either commercially available or were generated in the laboratories of Alessandro Moretta and Silvia Parolini.

To analyze the expression of NK cell surface markers, five different tubes were prepared (Table [2](#T2){ref-type="table"}), each of which contained FITC-conjugated antibodies directed against CD3, CD20, and CD14, to gate out T cells, B cells, and monocytes. Furthermore, tube \#1 contained isotype controls, whereas tubes \#2--5 contained antibodies to NK cell markers.

###### 

Combination of antibodies used to characterize natural killer cell phenotype.

  Tube \#   Antibody                                  Source
  --------- ----------------------------------------- -------------------------
  1         IgG1 isotype control                      Biolegend
            IgG2a isotype control                     Biolegend
            IgG2b isotype control                     Biolegend
            PE-conjugated goat anti-mouse IgG1        Southern Biotech
            PE-conjugated goat anti-mouse IgG2a       Southern Biotech
            PE/Cy7-conjugated goat anti-mouse IgG2b   Southern Biotech
            FITC-conjugated anti-CD3                  Beckman Coulter
            PC5-conjugated anti-CD56                  Beckman Coulter
            FITC-conjugated anti-CD14                 Beckman Coulter
            FITC-conjugated anti-CD20                 Biolegend
            APC/Cy7-conjugated IgG1                   Biolegend
            BV510-conjugated IgG1                     Biolegend
            BV421-conjugated mouse IgM                Becton-Dickinson
  2         Anti-NKG2A (Z199) \[IgG2b\]               A. Moretta, S. Parolini
            Anti-KIR2 DL1/S1 (AZ115) \[IgG1\]         A. Moretta, S. Parolini
            Anti-KIR2 DL2/S2 (GL183) \[IgG1\]         A. Moretta, S. Parolini
            Anti-KIR3D (AZ158) \[IgG2a\]              A. Moretta, S. Parolini
            PE-conjugated goat-anti-mouse IgG1        Southern Biotech
            PE-conjugated goat anti-mouse IgG2a       Southern Biotech
            PE/Cy7-conjugated goat anti-mouse IgG2b   Southern Biotech
            FITC-conjugated anti-CD3                  Beckman Coulter
            PC5-conjugated anti-CD56                  Beckman Coulter
            FITC-conjugated anti-CD14                 Beckman Coulter
            FITC-conjugated anti-CD20                 Biolegend
            APC/Cy7-conjugated anti-CD16              Biolegend
            BV510-conjugated anti-CD69                Biolegend
            BV421-conjugated anti-CD57                Becton-Dickinson
  3         Anti-SIGLEC7 (Z176) \[IgG2b\]             A. Moretta, S. Parolini
            Anti-LIR1 (F278) \[IgG1\]                 A. Moretta, S. Parolini
            PE-conjugated goat-anti-mouse IgG1        Southern Biotech
            PE/Cy7-conjugated goat anti-mouse IgG2b   Southern Biotech
            FITC-conjugated anti-CD3                  Beckman Coulter
            PC5-conjugated anti-CD56                  Beckman Coulter
            FITC-conjugated anti-CD14                 Beckman Coulter
            FITC-conjugated anti-CD20                 Biolegend
            APC/Cy7-conjugated anti-CD16              Biolegend
            BV510-conjugated anti-CD69                Biolegend
            BV421-conjugated anti-CD57                Becton-Dickinson
  4         Anti-NKG2C \[IgG2b\]                      R&D Systems
            Anti-KIR2 DL1/S1 (11PB6) \[IgG1\]         A. Moretta, S. Parolini
            Anti-KIR2 DL2/S2 (GL183) \[IgG1\]         A. Moretta, S. Parolini
            Anti-KIR3D (AZ158) \[IgG2a\]              A. Moretta, S. Parolini
            PE-conjugated goat-anti-mouse IgG1        Southern Biotech
            PE-conjugated goat anti-mouse IgG2a       Southern Biotech
            PE/Cy7-conjugated goat anti-mouse IgG2b   Southern Biotech
            FITC-conjugated anti-CD3                  Beckman Coulter
            PC5-conjugated anti-CD56                  Beckman Coulter
            FITC-conjugated anti-CD14                 Beckman Coulter
            FITC-conjugated anti-CD20                 Biolegend
            APC/Cy7-conjugated anti-CD16              Biolegend
            BV510-conjugated anti-CD69                Biolegend
            BV421-conjugated anti-CD57                Becton-Dickinson
  5         Anti-CXCR1 \[IgG1\]                       Santa Cruz
            PE-conjugated goat-anti-mouse IgG1        Southern Biotech
            FITC-conjugated anti-CD3                  Beckman Coulter
            PC5-conjugated anti-CD56                  Beckman Coulter
            FITC-conjugated anti-CD14                 Beckman Coulter
            FITC-conjugated anti-CD20                 Biolegend
            APC/Cy7-conjugated anti-CD16              Biolegend
            Pacific Blue-conjugated anti-CCR7         Biolegend

Analysis of Perforin Expression {#S2-3}
-------------------------------

Intracellular content of perforin was analyzed in a limited number of patients with SCID/OS/AS due to RAG/NHEJ defects and in healthy infants. Briefly, PBMCs were first stained with a mixture of FITC-conjugated mAbs directed against CD3, CD20, and CD14, as well as with PC5-labeled anti-CD56 mAb, and incubated for 30 min at 4°C. After treatment with 200 µl of Cytofix/Cytoperm (BD-Bioscience, Pharmigen CA, USA) for 20 min at 4°C, cells were washed with 1 ml of saponin (0.1% solution in PBS), and then stained with 5 µl of purified R-PE-labeled anti-perforin mAb (Ancell). After washing, the proportion of CD3^−^ CD14^−^ CD20^−^ CD56^+^ cells expressing perforin and the mean fluorescent intensity (MFI) of perforin were immediately analyzed on LSR Fortessa Flow Cytometer (BD) using FACSDiva software (BD). Final analysis was done using FloJo v.10.2 (TreeStar).

Analysis of NK Cell Degranulation {#S2-4}
---------------------------------

Natural killer cell degranulation activity was tested against the K562 erythroleukemia human cell line. In particular, PBMCs derived from patients and from healthy donors were obtained upon Ficoll separation of heparinized blood samples, and incubated with or without 100 U/mL recombinant human IL-2 (NIH) at 37°C overnight. Cells were then incubated with target cells at an effector:target ratio of 1:3 in a final volume of 200 µl in round-bottomed 96-well plates at 37°C and 5% CO2 for 4 h in culture medium supplemented with anti-CD107a-PE (BD Biosciences Pharmingen, San Diego, CA, USA) monoclonal antibody. Cells were then surface-stained with FITC anti-CD3, PC5 anti-CD56, FITC anti-CD14 (Beckman Coulter), FITC anti-CD20, and APC/Cy7 anti-CD16 (BD Biosciences Pharmingen, San Diego, CA, USA) Ab for 30 min at 4°C. The cells were washed, and the proportion of CD3^−^ CD14^−^ CD20^−^ CD56^+^ cells expressing CD107a was analyzed immediately on LSR Fortessa Flow Cytometer (BD) using FACSDiva v6.1.3 software (BD Biosciences, Mountain View, CA, USA). Final analysis was performed using FloJo v.10.2 (TreeStar). The threshold to define CD107a expression in cells co-cultured with K562 target cells (in the presence or absence of IL-2) was set up on cells cultured with IL-2 alone, without K562 cells.

Analysis of Interferon-γ (IFN-γ) Production {#S2-5}
-------------------------------------------

To detect intracellular production of IFN-γ, PBMCs from patients and healthy donors were incubated overnight at 37°C with IL-12 (0.5 ng/ml), or IL-12 (0.5 ng/ml) and IL-18 (0.1 ng/ml) combined. Surface staining was done by incubating the cells with FITC anti-CD3, PC5 anti-CD56, FITC anti-CD14 (Beckman Coulter), FITC anti-CD20, and APC/Cy7 anti-CD16 (BD) mAbs for 30 min at 4°C. Cells were then washed, fixed, and permeabilized with BD Cytofix/Cytoperm kit (BD Biosciences Pharmingen). IFN-γ production was detected by subsequent intracellular staining with PE-conjugated anti-IFN-γ (BD Biosciences Pharmingen). After washing, the proportion of CD3^−^ CD14^−^ CD20^−^ CD56^+^ cells expressing IFN-γ was immediately analyzed on LSR Fortessa Flow Cytometer (BD) using FACSDiva software (BD). Final analysis was done using FloJo v.10.2 (TreeStar).

Statistical Analysis {#S2-6}
--------------------

Statistical analysis of the *in vitro* recombination activity of mutant RAG and ARTEMIS proteins, and of the expression of NK cell markers in patients and controls was performed using Mann--Whitney test for non-parametric variables.

Results {#S3}
=======

Demographic and Clinical Features {#S3-1}
---------------------------------

At the time of evaluation, mean age (±SEM) was significantly lower in patients with SCID (7.1 ± 1.72 months; range: 0.25--28 months) and in those with OS/AS (15.96 ± 5.41 months; range: 24--480 months) than in patients with CID (177.2 ± 28.22 months; range: 24--480 months; *p* \< 0.0001).

A clinical history of significant infections was present in 60 patients with RAG/NHEJ gene defects (Table [1](#T1){ref-type="table"}). Candida (*n* = 11), *Pseudomonas* (*n* = 7), human papillomavirus (HPV, *n* = 7), adenovirus (*n* = 6), varicella zoster virus (VZV, *n* = 6), *Pneumocystis jiroveci* (*n* = 5), Bacillus Calmette-Guerin (BCG, *n* = 5), and rhinovirus (*n* = 5) were the most common pathogens. In particular, *P. jiroveci* pneumonia was observed only in patients with SCID or OS/AS, whereas severe VZV infection was mostly restricted to patients with CID. Cytomegalovirus (CMV) and Epstein--Barr virus (EBV) infections were documented in 13 patients each, but were clinically significant only in 4 and 3 patients, respectively. Two SCID patients (P4 and P11) were diagnosed at birth following newborn screening, and infections were effectively prevented with isolation and prophylactic antimicrobials.

Autoimmunity and/or autoantibody production were documented in 23 patients, and were more common in patients presenting with CID (14 out of 21 patients) than in those with SCID (0/19) or with OS/AS (9/24). Cytopenias were the most frequent manifestation of autoimmunity and were documented in 11 patients (4 with OS/AS and 7 with CID). Alopecia and/or vitiligo were observed in six CID patients. Granulomatous disease was present in eight patients with CID. Finally, 12 patients (P20--P31) had typical features of OS (generalized erythroderma, lymphadenopathy, hepatosplenomegaly).

Immunological Phenotype {#S3-2}
-----------------------

The count of circulating CD3^+^, CD19^+^, and CD3^−^ CD56^+^ cells in patients belonging to the various groups (SCID, OS/AS, and CID) is shown in Figure [1](#F1){ref-type="fig"}. With the exception of one SCID patient (P19) who had a high count of maternal T cells (13997 cells/μl), all others had severe T cell lymphopenia (Figure [1](#F1){ref-type="fig"}A). By contrast, a higher count of autologous T cells was recorded in patients with CID and especially in patients with OS/AS. B cell lymphopenia was observed in the vast majority of patients, irrespective of the clinical phenotype (Figure [1](#F1){ref-type="fig"}B). By contrast, NK cell count was either normal or increased in most patients (Figure [1](#F1){ref-type="fig"}C).

![Absolute count of T **(A)**, B **(B)**, and natural killer (NK) **(C)** lymphocytes at the time of evaluation of NK cell phenotype and function. The area shown in shaded gray represents normal values for age. Different symbols (circle, square, diamond) are used to indicate patients with severe combined immune deficiency (SCID), Omenn syndrome/atypical SCID (OS/AS), and delayed onset combined immune deficiency (CID), respectively. Open circles identify patients with mutations of the recombinase-activating gene (RAG), and close symbols identify patients with mutations in genes involved in non-homologous end joining (NHEJ).](fimmu-08-00798-g001){#F1}

Data on *in vitro* proliferation to phytohemagglutinin (PHA) were available in 51 patients. Response was absent (\<10% of lower limit of normal, LLN) in 17, markedly reduced (10--30% of LLN) in 11, reduced (\>30% of LLN, but lower than LLN) in 14, and normal in 9 patients. T cell proliferation to PHA was better preserved in patients with CID; among 18 such patients for whom information was available, 15 had either normal (*n* = 7) or reduced (*n* = 8) response.

Low serum levels of IgA and IgM were detected in the majority of SCID patients (Table [1](#T1){ref-type="table"}); serum IgG in this group was less informative because of the presence of maternally derived immunoglobulins. Immunoglobulin levels were more variable in patients with OS/AS and in those with CID. In particular, among 23 CID patients, 17 had either low serum IgG (*n* = 9) or were under immunoglobulin replacement therapy (*n* = 8) and 15 had undetectable serum IgA.

Correlation between Clinical Phenotype and Recombination Activity Sustained by the Mutant Alleles {#S3-3}
-------------------------------------------------------------------------------------------------

Molecular analysis of the patients included in this study identified a total of 41 *RAG1*, 16 *RAG2*, 11 *DCLRE1C*, 4 *LIG4*, and 2 *NHEJ* distinct gene mutations (Table [1](#T1){ref-type="table"}). Using a flow cytometry-based assay, we have previously reported correlation between recombination activity supported by *RAG* and *DCLRE1C* mutant alleles and the clinical and immunological disease phenotype ([@B22], [@B32]). For the patient cohort included in this study, data on *in vitro* recombination activity were available for 36 *RAG1*, 9 *RAG2*, and 6 *DCLRE1C* mutant alleles. Upon plotting for each patient the recombination activity associated with each of the two mutant alleles, a significant genotype--phenotype correlation was observed, with higher residual recombination activity for mutant alleles associated with a CID phenotype than for those associated with OS/AS or SCID (Figure [2](#F2){ref-type="fig"}).

![Graphical representation of the recombination activity (mean ± SD) of *RAG* and *DCLRE1C* mutant alleles in patients with severe combined immune deficiency (SCID), Omenn syndrome/atypical SCID (OS/AS), and delayed onset combined immune deficiency (CID). \**p* \< 0.05; \*\*\**p* \< 0.005; \*\*\*\**p* \< 0.001.](fimmu-08-00798-g002){#F2}

Circulating NK Cells from Healthy Infants Comprise a High Proportion of CD56^bright^ Cells {#S3-4}
------------------------------------------------------------------------------------------

According to a widely accepted scheme, human NK cell differentiation is marked by changes in the expression of cell surface and intracytoplamsic markers, so that five distinct stages of NK cell development are recognized ([@B33]). In peripheral blood from healthy controls, both stage 4 (CD56^bright^ CD16^−^) and stage 5 (CD56^+^ CD16^hi^) NK cells are detectable. In particular, in normal adults, CD56^bright^ CD16^−^ cells account for only 5--10% of all circulating NK cells. By contrast, a higher percentage of CD56^bright^ cells was detected in healthy infants (Figures [3](#F3){ref-type="fig"}A,B). Moreover, the proportion of CD16^+^ cells was lower in infants than in healthy controls greater than 2 years of age (Figures [3](#F3){ref-type="fig"}A,C). Finally, NK cells from healthy infants included a lower proportion of cells expressing CD57 (Figures [3](#F3){ref-type="fig"}A,D), KIRs (Figures [3](#F3){ref-type="fig"}A,E), and CXCR1 (Figures [3](#F3){ref-type="fig"}A,F), whereas the percentage of NK cells expressing NKG2A was higher in infants than in older healthy controls (Figures [3](#F3){ref-type="fig"}A,G).

![Flow cytometry analysis of natural killer cell phenotype in healthy infants (\<2 years of age) and healthy donors \>2 years of age. **(A)** Representative analysis of the expression of CD56, CD16, CD57, killer cell immunoglobulin-like receptors (KIRs), CXCR1, and NKG2A in a healthy infant and a healthy donor \>2 years of age; **(B--G)** percentage of CD56^bright^ **(B)**, CD16^+^ **(C)**, CD57^+^ **(D)**, KIR^+^ **(E)**, CXCR1^+^ **(F)**, and NKG2A^+^ **(G)** cells upon gating on CD3^−^ CD19^−^ CD14^−^ CD56^+^ cells. For NKG2A, different gates are shown to indicate NKG2A^+^, NKG2A^++^, and NKG2A^+++^ cells. For each marker, positivity was defined as fluorescence intensity above that of isotype control. Bars represent mean ± SD values. \*\**p* \< 0.01; \*\*\*\**p* \< 0.001.](fimmu-08-00798-g003){#F3}

Markedly Increased Proportion of CD56^bright^ NK Cells in the Peripheral Blood of Patients with RAG and NHEJ Defects Correlates with the Clinical Phenotype {#S3-5}
-----------------------------------------------------------------------------------------------------------------------------------------------------------

A recent study in *Rag^−/−^* mice has unexpectedly disclosed abnormalities of NK phenotype and function, with increased proportion of mature, activated cells with increased cytotoxic activity and reduced survival ([@B30]). In order to assess whether similar abnormalities exist in patients with RAG or NHEJ defects, and to establish whether such abnormalities, if present, correlate with the severity of the clinical phenotype and with residual function of the mutant protein, we have analyzed the expression of CD56 and CD16 on the surface of CD3^−^ CD14^−^ CD20^−^ peripheral blood NK cells from patients and controls. As shown in Figures [4](#F4){ref-type="fig"}A,B, patients with SCID due to RAG/NHEJ defects had a high proportion of CD56^bright^ CD16^−^ NK cells (mean ± SEM: 34.7 ± 4.4), that exceeded what was observed in healthy infants (13.9 ± 3.3; *p* = 0.0007). Similarly, the proportion of CD56^bright^ CD16^−^ NK cells was higher in patients with CID than in healthy controls greater than 2 years of age (10.4 ± 1.8 vs. 5.1 ± 0.7; *p* = 0.0431; Figures [4](#F4){ref-type="fig"}A,B). Among infants with RAG/NHEJ defects, the proportion of CD56^bright^ CD16^−^ NK cells was higher in those presenting with SCID than in those with OS/AS (*p* = 0.0008; Figure [4](#F4){ref-type="fig"}B). In order to investigate whether the increase in the proportion of CD56^bright^ NK cells was secondary to numerical and/or functional abnormalities of T and/or B cells, we also analyzed a group of patients with other forms of TCD or with XLA. The proportion of CD56^bright^ CD16^−^ NK cells in these groups was similar to that of healthy controls, and significantly lower than in patients with SCID due to RAGH/NHEJ defects (Figure [4](#F4){ref-type="fig"}B). Among patients with TCD, no correlation was observed among the proportion of CD56^bright^ NK cells and the severity of T cell lymphopenia, indicating that the increase of CD56^bright^ NK cells observed in SCID patients with RAG/NHEJ defects is not simply secondary to T cell lymphopenia. Furthermore, the proportion of CD56^bright^ CD16^int^ NK cells, that are considered to represent an intermediate step of differentiation between CD56^bright^ CD16^−^ and CD56^dim^ CD16^hi^ cells, was significantly higher in infants with SCID due to RAG/NHEJ defects than in healthy infants, patients with TCD or with XLA (*p* \< 0.0001; Figure [4](#F4){ref-type="fig"}C). A higher percentage of CD56^bright^ CD16^int^ NK cells was also observed in patients with CID than in healthy controls greater than 2 years of age (*p* \< 0.05; Figure [4](#F4){ref-type="fig"}C). Finally, patients with SCID due to RAG/NHEJ defects had a lower proportion of CD56^dim^ CD16^hi^ NK cells when compared to healthy infants (*p* = 0.0007; Figure [4](#F4){ref-type="fig"}D). Similar results were obtained when comparing patients with CID versus healthy controls older than 2 years of age (*p* = 0.0011).

![Flow cytometry analysis of CD56 and CD16 expression in natural killer cells from patients and controls. **(A)** Representative analysis of the expression of CD56 and CD16 in CD3^−^ CD19^−^ CD14^−^ CD56^+^ cells from one patient each belonging to the severe combined immune deficiency (SCID), Omenn syndrome (OS), delayed-onset combined immune deficiency (CID), other forms of T cell defect (TCD), and X-linked agammaglobulinemia (XLA), respectively. **(B--D)** Percentage of CD56^bright^ CD16^−^ **(B)**, CD56^bright^ CD16^int^ **(C)**, and CD56^dim^ CD16^hi^ **(D)** cells among CD3^−^ CD19^−^ CD14^−^ CD56^+^ cells. For each marker, positivity was defined as fluorescence intensity above that of isotype control. Bars represent mean ± SD values. \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.005; \*\*\*\**p* \< 0.001.](fimmu-08-00798-g004){#F4}

CD56^bright^ NK Cells from Infants with RAG/NHEJ Defects Have an Immature Phenotype {#S3-6}
-----------------------------------------------------------------------------------

The data reported above on CD56 and CD16 surface expression indicate that patients with RAG/NHEJ defects have an abnormal distribution of NK cell subsets, with an increased proportion of more immature cells as compared to what is observed in healthy controls. In order to further confirm this, we analyzed the expression of additional surface markers that are differentially expressed in CD56^bright^ versus more mature CD56^dim^ NK cells. As compared to healthy controls \>2 years of age, patients with CID had a lower proportion of CD57^+^ NK cells (*p* = 0.0022; Figures [5](#F5){ref-type="fig"}A,B). Furthermore, patients with SCID had fewer CD57^+^ NK cells than patients with other forms of TCD (*p* = 0.0041), and a similar trend was also observed when compared to infant controls, although the difference did not reach statistical significance (Figure [5](#F5){ref-type="fig"}B).

![Flow cytometry analysis of the expression of CD57 **(A,B)**, NKG2A **(C,D)**, and CXCR1 **(E,F)**, and killer cell immunoglobulin-like receptors (KIRs) **(G,H)** among CD3^−^ CD19^−^ CD14^−^ CD56^+^ cells. In panels **(A,C,E,G)**, representative examples are shown for one patient each belonging to the severe combined immune deficiency (SCID), Omenn syndrome (OS), and delayed-onset combined immune deficiency (CID) subgroups. For each marker, positivity was defined as fluorescence intensity above that of isotype control. Bars represent mean ± SD values. \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.005; \*\*\*\**p* \< 0.001.](fimmu-08-00798-g005){#F5}

In normal subjects, circulating stage 4 CD56^bright^ NK cells are characterized by high levels of expression of NKG2A and of the chemokine receptor CCR7, which facilitates homing to lymphoid tissues. By contrast, expression of KIRs and of the chemokine receptor CXCR1 is virtually absent in CD56^bright^ NK cells. As compared to healthy controls, the proportion of NK cells expressing NKG2A at high density was increased in patients with SCID and CID due to RAG/NHEJ defects (Figures [5](#F5){ref-type="fig"}C,D), and by contrast, the percentage of CXCR1^+^ NK cells was reduced (Figures [5](#F5){ref-type="fig"}E,F). Furthermore, patients with SCID due to RAG/NHEJ defects had a lower proportion of NK cells expressing KIR than healthy infants, patients with OS and those with other forms of TCD (Figures [5](#F5){ref-type="fig"}G,H). While the proportion of CCR7^+^ cells was higher in healthy infants than in healthy controls \>2 years of age (Figure [6](#F6){ref-type="fig"}), no significant differences were observed in the percentage of CCR7^+^ NK cells between patients with RAG/NHEJ defects and healthy controls. Notably, CCR7 expression was downregulated during the transition from CD56^bright^ CD16^−^ to CD56^bright^ CD16^int^ cells (data not shown). Furthermore, the proportion of NK cells expressing Siglec-7, leukocyte Ig-like receptor (LIR)-1, or the activation marker CD69 was similar in patients and healthy controls, although interestingly a high proportion of Siglec-7^+^ NK cells were detected in the control group of patients with XLA (Figure [6](#F6){ref-type="fig"}). Overall, these data support the notion that the CD56^bright^ NK cells that are more abundant in patients with RAG/NHEJ defects represent immature NK cells and provide evidence for a genotype--phenotype correlation in this group of diseases.

![Percentage of CD3^−^ CD19^−^ CD14^−^ CD56^+^ cells expressing CCR7 (left panel), Siglec-7 (middle panel), or CD69 (right panel) in patients and controls. For each marker, positivity was defined as fluorescence intensity above that of isotype control. Bars represent mean ± SD values. \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.005; \*\*\*\**p* \< 0.001.](fimmu-08-00798-g006){#F6}

Impact of Viral Infections on NK Cell Phenotype {#S3-7}
-----------------------------------------------

Recombinase-activating gene and NHEJ defects lead to increased susceptibility to viral infections, including CMV, EBV, and VZV. It has been reported that viral infections (and CMV in particular) may lead to significant changes of NK cell phenotype and function, with accumulation of cytotoxic CD56^dim^ NKG2C^+^ NKG2A^−^ KIR^+^ CD57^+^ cells ([@B34]). Expansion of these cells does not require T cells, as shown in an IL7R-deficient SCID infant after CMV infection ([@B35]). A significant proportion (26/66, 39.4%) of the patients with RAG/NHEJ defects included in this study had a documented history of CMV, EBV, VZV or severe JC virus (JCV) infection (Table [1](#T1){ref-type="table"}). The proportion of NK cells expressing NKG2C was not statistically different in patients with SCID, OS/AS, or CID versus healthy controls (Figure [7](#F7){ref-type="fig"}A). Furthermore, when patients were divided into two groups according to their history of CMV, EBV, VZV, or severe JCV infection, no differences were observed in the proportion of NKG2C^+^ NK cells (Figure [7](#F7){ref-type="fig"}B). Even when patients with SCID/OS/AS or with CID were divided into two subgroups based on their CMV infection history, no difference was observed in the proportion of NKG2C^+^ (Figure [7](#F7){ref-type="fig"}C) and of CD56^dim^ (Figure [7](#F7){ref-type="fig"}D) NK cells. Finally, although a higher percentage of "exhausted" NK cells with a CD56^−^ CD16^+^ CD57^+^ phenotype was detected in patients with SCID, OS/AS, and TCD than in healthy infants (Figure [7](#F7){ref-type="fig"}E), no correlation was observed with a history of viral infections.

![**(A)** Percentage of NKG2C^+^ cells among CD3^−^ CD19^−^ CD14^−^ CD56^+^ cells from patients and controls. **(B)** Percentage of NKG2C^+^ cells among natural killer (NK) cells from patients with recombinase-activating gene (RAG)/non-homologous end-joining (NHEJ) defects with positive (+) or negative (−) history of infections due to cytomegalovirus (CMV), Epstein--Barr virus (EBV), varicella zoster virus (VZV), or JC virus (JCV). **(C)** Percentage of NKG2C^+^ cells among NK cells from patients with RAG/NHEJ defects presenting with severe combined immune deficiency (SCID), Omenn syndrome/atypical SCID (SCID/OS/AS), or with delayed onset combined immune deficiency (CID), and divided into two groups according to the presence (+) or absence (−) of a history of CMV infection. **(D)** Percentage of CD56^dim^ CD16^+^ cells among NK cells from patients with RAG/NHEJ defects presenting with SCID/OS/AS or with CID, and with either positive (+) or negative (−) history of CMV infection. **(E)** Percentage of CD56^−^ CD16^+^ CD57^+^ cells among CD3^−^ CD14^−^ CD20^−^ peripheral blood mononuclear cells. Bars represent mean ± SD values. \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.005.](fimmu-08-00798-g007){#F7}

CD56^bright^ Cells from Patients with RAG/NHEJ Defects Are Potent Producers of IFN-γ {#S3-8}
------------------------------------------------------------------------------------

Circulating CD56^bright^ NK cells serve an immunoregulatory function through secretion of various cytokines (IFN-γ, TNF-α, IL-10) ([@B36]). In order to assess this aspect of NK cell function, we performed *in vitro* stimulation with IL-12 and IL-18, and analyzed intracellular expression of IFN-γ upon gating separately on CD56^bright^ vs. CD56^dim^ NK cells. As expected, in both patients and controls CD56^bright^ cells were more potent producers of IFN-γ than CD56^dim^ cells, but both subsets were capable of producing this cytokine (Figure [8](#F8){ref-type="fig"}). However, CD56^dim^ cells from patients with SCID and with OS/AS due to RAG/NHEJ defects showed impaired IFN-γ production when compared to equivalent cells from healthy infants or patients with TCD. A similar trend was observed in patients with CID versus healthy controls greater than 2 years of age (Figure [8](#F8){ref-type="fig"}).

![Percentage of interferon-γ (IFN-γ) expressing cells among CD56^bright^ and CD56^dim^ natural killer cells from patients and controls, upon *in vitro* stimulation with IL-12 and IL-18. Bars represent mean ± SD values. \**p* \< 0.05; \*\*\**p* \< 0.005; \*\*\*\**p* \< 0.001.](fimmu-08-00798-g008){#F8}

NK Cells from Patients with SCID due to RAG/NHEJ Defects Have Increased Degranulation Capacity in the Absence of IL-2-Mediated Stimulation, and Express a Higher Amount of Intracellular Perforin than NK Cells from Healthy Infant Controls {#S3-9}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Previous data had shown that NK cells from *rag^−/−^* mice have increased cytotoxic activity ([@B30]). To investigate the cytolytic machinery of NK cells, we have analyzed NK cell degranulation in response to K562 target cells, in the absence or presence of IL-2. It is well known that human CD56^bright^ NK cells have reduced cytotoxic activity when compared to CD56^dim^ cells ([@B8]). In spite of the markedly increased proportion of CD56^bright^ NK cells, we observed that in the absence of stimulation with IL-2, NK cells from patients with SCID due to RAG/NHEJ defects have increased degranulation capacity when compared to NK cells from healthy infants (Figure [9](#F9){ref-type="fig"}A, left panel). In particular, CD56^dim^ NK cells from patients with SCID showed increased degranulation when compared to the equivalent subset of NK cells from healthy infants (Figure [9](#F9){ref-type="fig"}A, middle panel). A similar trend was observed also for CD56^bright^ NK cells, but the difference between SCID patients and controls did not reach statistical significance (Figure [9](#F9){ref-type="fig"}A, middle panel). Stimulation with IL-2 significantly increased NK cell degranulation capacity to similar levels in patients and controls (Figure [9](#F9){ref-type="fig"}A, right panel). Although the amount of intracellular perforin could be measured only in a small number of patients with SCID, a significantly higher mean fluorescent intensity (MFI) was observed in unstimulated NK cells from patients than from healthy infants (Figure [9](#F9){ref-type="fig"}B).

![**(A)** Natural killer (NK) cells degranulation, expressed as percentage of CD107a^+^ cells, upon co-culture of peripheral blood mononuclear cells from patients with severe combined immune deficiency (SCID) and healthy infants with K562 target cells, in the absence (left and middle panels) or presence (right panel) of stimulation with exogenous interleukin-2 (IL-2). The middle panel shows degranulation of CD56^bright^ (left) and CD56^dim^ (right) NK cells from SCID patients and healthy infants in the absence of IL-2 stimulation. **(B)** Representative example (left) of perforin expression in resting NK cells from a patient with SCID due to RAG defect (red) and a healthy infant (blue), and mean fluorescent intensity (MFI) of perforin expression (right) in patients with SCID/OS/AS due to recombinase-activating gene (RAG)/non-homologous end-joining (NHEJ) defects and healthy infants. Bars represent mean ± SD values. \**p* \< 0.05; \*\**p* \< 0.01.](fimmu-08-00798-g009){#F9}

Discussion {#S4}
==========

In this manuscript, we have demonstrated that NK cells from healthy infants comprise a higher proportion of CD56^bright^ CD16^−/int^ CD57^−^ cells than what is observed in older healthy subjects, confirming previous observations ([@B37]--[@B39]). Several lines of evidence indicate that CD56^bright^ cells represent precursors to CD56^dim^ cells. In particular, it has been demonstrated that appearance of CD56^bright^ cells precedes that of CD56^dim^ cells after HSCT ([@B40]) and that it is possible to induce differentiation of CD56^bright^ into CD56^dim^ NK cells *in vitro* in response to signaling *via* fibroblast growth factor receptor 1 ([@B41]). On the other hand, the model according to which CD56^bright^ cells precede CD56^dim^ cells during NK cell development has been challenged by NK cell lineage tracking experiments with genetic bar coding in macaques, which have suggested that these subsets may have distinct ontogeny ([@B42]).

In any case, the demonstration that composition of the peripheral NK cell compartment varies with age indicates that appropriate age-matched controls should be used when analyzing NK cell phenotype in pathological conditions.

In particular, by performing an extensive phenotypic analysis, we have shown that NK cells from patients with RAG/NHEJ defects comprise a higher proportion of CD56^bright^ CD16^−/int^ NKG2A^+++^ cells, and a reduced percentage of CD56^dim^ CD16^hi^ cells expressing CD57, KIRs, and CXCR1, than observed in age-matched healthy controls. Altogether, these observations suggest that NK cells from patients with RAG/NHEJ defects have a more immature phenotype when compared to age-matched healthy controls, in spite of the fact that NK cells from CID patients showed signs of progressive differentiation as compared to NK cells from patients with SCID/OS/AS. These data contrast with recent findings in *Rag^−/−^* mice, whose peripheral NK cell compartment is characterized by a predominance of cells expressing KLRG1, a marker of mature NK cells ([@B30]). Furthermore, peripheral NK cells from *Rag^−/−^* mice are largely CD62L^−^, indicating an *in vivo* activated phenotype ([@B30]). By contrast, we did not observe increased expression of CD69, an activation marker ([@B43]), in NK cells from patients with RAG/NHEJ defects, including those with OS, a condition characterized by accumulation of *in vivo*-activated autologous T cells. While the reasons for these discrepancies are not clear, murine and human NK cells differ substantially, also in regard to phenotypic markers that are differentially expressed during development.

By affecting the process of V(D)J recombination, mutations in *RAG* and NHEJ genes profoundly affect generation of T and B lymphocytes. Consistent with this, patients with *RAG*/NHEJ gene defects had a markedly reduced number of circulating B and T cells, with the exception of patients with OS, some of which had a normal or even increased number of oligoclonal and activated T cells, as typically observed in this disease. Previous studies in TCRβδ*^−/−^* and in μMT*^−/−^* mice had demonstrated that lack of T and B cells have opposite effects on the count of splenic NK cells. In particular, T cell deficiency is associated with a twofold to threefold increase, and B cell deficiency with a twofold to threefold decrease of NK cell count as compared to C57BL/6 wild-type mice ([@B44]). The patients with RAG and NHEJ defects included in this study had either normal or increased count of circulating NK cells. In order to rule out the possibility that their abnormalities of NK cell phenotype could be secondary to T and B cell lymphopenia, we have included in this study patients with XLA (who lack circulating B cells) and with other forms of TCD, including seven patients with SCID not due to RAG/NHEJ defects. Even when compared to these two control groups, patients with SCID due to RAG/NHEJ gene defects had a markedly increased proportion of CD56^bright^ CD16^−^ CD57^−^ NKG2A^+++^ cells. Similar differences were also observed also when comparing NK cells from patients with OS/AS and those with TCD or XLA, with an increased percentage of CD56^bright^ CD16^−^ CD57^−^ cells in the former. Altogether, these data indicate that the increased representation of immature cells within the peripheral NK cell compartment of patients with RAG/NHEJ defects is not secondary to T and B cell lymphopenia.

Because of their severe T cell immunodeficiency, patients with RAG/NHEJ defects are highly prone to viral infections, including CMV. LIR-1 is a member of the immunoglobulin superfamily which has been shown to bind the human CMV MHC class I homolog UL-18 protein ([@B45]). NKG2A and NKG2C represent inhibitory and activating forms of CD94, recognizing non-classical HLA-E molecules ([@B46]). CMV infection can drive expansion of KIR^+^ and/or LIR-1^+^, NKG2A^−^ NKG2C^+^ NK cells ([@B34]). Furthermore, rapid differentiation of CD56^dim^ NKG2C^+^ NKG2A^−^ CD57^+^ cells has been observed after CMV reactivation in recipients of HSCT ([@B47]). It has been shown that upon transfer from CMV-seropositive donors into seropositive HSCT recipients, NKG2C^+^ cells undergo expansion and produce high amounts of IFN-γ as compared to NKG2C^+^ cells transfused into CMV-seronegative recipients, implying that NKG2C^+^ cells may represent "memory" NK cells capable of a prompt response upon re-exposure to CMV ([@B48]). Finally, rapid expansion of NKG2C^+^ NK cells has been reported in infants acquiring perinatal CMV infection ([@B39]). Although several of the patients included in this study had a history of CMV infection, no particular expansion of NKG2C^+^ and/or LIR-1^+^ cells was observed. Monocytes are apparently required to allow expansion of adaptive/memory-like NK cells ([@B49]). Lack of expansion of NKG2C^+^ cells in CMV-infected, RAG-/NHEJ mutated SCID patients may reflect a requirement also for T cell help in this process and may further contribute to poor control of CMV infection in these patients.

CD56^bright^ and CD56^dim^ NK cells differ in their immunomodulatory and effector function. In particular, CD56^bright^ cells are potent producers of IFN-γ, but have lower content of perforin and display reduced cytotoxic activity as compared to CD56^dim^ cells. Analysis of IFN-γ production by CD56^bright^ and CD56^dim^ NK cells from patients and controls confirmed that CD56^bright^ cells were more potent producers of IFN-γ, irrespective of the underlying diagnosis. However, the proportion of CD56^dim^ NK cells producing IFN-γ was lower in patients with SCID/OS/AS due to RAG/NHEJ defects than in healthy infants or in patients with other forms of TCD, and a similar trend was observed for CD56^dim^ cells from CID patients. These results suggest that RAG/NHEJ defects are associated with abnormalities of NK cells that are not restricted to their phenotype, but may also involve NK cell function. In this regard, it is particularly significant that NK cells from the patients displayed enhanced degranulation in the absence of previous stimulation with IL-2, and that CD56^bright^ cells from patients with SCID/OS/AS had a higher content of perforin than CD56^bright^ cells from healthy infants. Although we did not perform a chromium release assay to investigate NK cytolytic function, these data suggest that RAG/NHEJ defects are associated with enhanced effector function, similarly to what was previously reported for *Rag^−/−^* mice ([@B30]).

Expression of RAG may initiate prior to T and B cell differentiation, as indicated by the presence of incomplete rearrangements at the immunoglobulin heavy chain or T cell receptor loci in a minority of murine and human NK cells ([@B29], [@B50]). It has been suggested that introduction of DNA double strand breaks in lymphoid progenitor cells would facilitate selection of cells with more efficient DNA repair machinery ([@B30]). In the absence of this mechanism, NK cells from Rag-deficient animals and humans would have reduced cellular fitness. Our data indicate that indeed patients with mutations in *RAG* or in NHEJ genes share similar abnormalities of NK cell phenotype and function. While it is not known whether the immunoglobulin and T cell receptor loci represent the only sites in the genome that are targeted by RAG during early stages of lymphoid development, it is interesting to note that selective loss of CD56^dim^ cells, with relative preservation of the CD56^bright^ NK cell compartment, has been reported in patients with mutations of *MCM4* and *POLE2* genes, all of which control DNA replication ([@B51]--[@B53]).

In conclusion, we have identified for the first time abnormalities of NK cell phenotype and function in patients with mutations in *RAG* and in genes involved in NHEJ. These abnormalities are more pronounced in patients with severe mutations associated with a more severe clinical and immunological phenotype, and are not secondary to T and B cell lymphopenia. Demonstration of enhanced degranulation activity and higher amount of perforin in NK cells from patients with SCID due to RAG/NHEJ defects suggests that inclusion of serotherapy targeting NK cells in the HSCT conditioning regimen may help reduce the risk of graft rejection that has been reported in these diseases.
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